Pittsburgh, PA (June 22, 2004)  -- Cellomics, Inc., the creator of High Content Screening (HCS), announced today it has entered into a non-exclusive, worldwide patent license agreement for its core HCS patent portfolio with GE Healthcare (a combination of the former Amersham and GE Medical Systems). 
In parallel, Cellomics and GE Healthcare have also entered into a limited term, exclusive agency agreement, which conveys to GE Healthcare rights to broker sublicenses of Cellomics’ HCS patent portfolio to key pharmaceutical companies.  Financial details of the two agreements were not disclosed.

“We are pleased to be working with GE Healthcare to broaden the availability of high content screening through the licensing of our HCS patent portfolio,” commented Daniel J. Calvo, President and CEO of Cellomics.Further, we are delighted GE Healthcare will be assisting us in sublicensing HCS, helping to meet the needs of customers and expanding the availability of critical technologies such as HCS to a wider group of scientists.”
“This relationship complements our strong portfolio of technologies for HCS.  Moreover, it reinforces GE Healthcare’s strategy of finding methods to help customers make informed decisions about progression through the drug development process,” stated Michael Evans, VP Marketing and Strategy, Discovery Systems.  “These agreements with Cellomics help us to enable customers to ask complex biological questions using our cellular sensors and, in turn, interpret the answers.”
Cellomics has more than 30 issued or allowed patents and an additional 30 patents pending in the field of HCS.  The company’s global patent portfolio includes both broad claims to HCS technology as well as specific classes of HCS assays such as cytoplasm-nuclear translocation, characterization of cellular toxicity, and receptor internalization.  “Cellomics developed a very strong intellectual property portfolio, while creating the market and products for HCS”, added D. Lansing Taylor, Founder and Cellomics Board Member. 
With nearly a decade of experience in developing and commercializing automated high content cell analysis solutions for drug discovery, and the largest user base behind it, Cellomics continues to develop complete solutions for drug discovery as well as life science researchers.  “Through our internal product development we have had a long history of providing tools for high content biological analyses,” continued Calvo.  “To complement our own product development, we have partnered with other companies on synergistic product solutions.  Now, in actively licensing our intellectual property, we are continuing to respond to and meet the needs of our customers, which will ultimately accelerate the availability of HCS technologies for all scientists.”  
About GE Healthcare
GE Healthcare provides transformational medical technologies that are shaping a new age of patient care.  GE Healthcare’s expertise in medical imaging and information technologies, medical diagnostics, patient monitoring systems, disease research, drug discovery and biopharmaceuticals is dedicated to detecting disease earlier and tailoring treatment for individual patients.  GE Healthcare offers a broad range of services to improve productivity in healthcare and enable healthcare providers to better diagnose, treat and manage patients with conditions such as cancer, Alzheimer’s and cardiovascular diseases.
GE Healthcare is a $14 billion unit of General Electric Company (NYSE: GE) that is headquartered in the United Kingdom.  Worldwide, GE Healthcare employs more than 42,500 people committed to serving healthcare professionals and their patients in more than 100 countries.  For more information about GE Healthcare, visit our website at www.gehealthcare.com.
About Cellomics
Cellomics, Inc is automating drug discovery through a unique, cell-based assay platform that addresses the needs of Drug Discovery and Systems Biology groups by offering complete systems for High Content Screening (HCS).  The platform includes HCS instrumentation (both fixed end-point and kinetic systems), informatics, cellular image analysis software (BioApplications), fluorescent reagents, kits, cell lines, and multiparametric assays.  When applied to early drug discovery, this platform is proving to reduce the 'idea-to-discovery' cycle time in drug discovery, while increasing the probability of the therapeutic success of leads as well as enhancing throughput in systems biology and basic research. Cellomics’ proprietary platforms, including the ArrayScan® and KineticScan® HCS Readers, along with the vHCS™ Discovery Toolbox software and BioApplications, are in use at multiple sites within all of the top fifteen pharmaceutical companies, as well as leading pharmaceutical and biotechnology companies and academic centers globally.  For more information about Cellomics, visit our website at www.cellomics.com.

For further information, contact:
Cellomics:
Judy P. Masucci, Ph.D.
Director of Marketing
Cellomics, Inc.
100 Technology Drive
Pittsburgh, PA 15219
412-770-2200 x 2353
412-770-2450 (fax)

GE Healthcare:
Helen Petts
Global PR Manager
GE Healthcare
tel: +44 (0) 1494 498 050